Providence Cancer Institute of Oregon

More than 20 presentations across 12 conferences highlight work in tumor immunology, molecular diagnostics, computational pathology and patient navigation.

Providence Cancer Institute is enrolling patients in a clinical trial to test Mo-Rez.

Providence Cancer Institute dietitian answers questions and offers helpful tips.

Many people with advanced NSCLC still need better treatment options. This study is evaluating an investigational medication that may help them live longer.

A sexual health professional at Providence helped Ellen regain her sense of self after treatment for endometrial cancer.

Del survived Arctic winters, a demanding career and cancer – twice. Here’s how a pioneering Providence Cancer Institute trial helped him beat it a second time.

Providence Cancer Institute is enrolling patients with hepatocellular carcinoma in a trial of pumitamig, an investigational bispecific antibody.

Prestigious grants will help researchers pursue important cancer studies.

An inside look at how a pharmacist at Providence Cancer Institute keeps clinical trials running safely, one dose at a time.

An expanded access program uses engineered T cells to target the KRAS G12D mutation in pancreatic, colorectal or other advanced cancers.

A new clinical trial is testing a promising drug combination that could improve survival for people whose cancer didn’t fully respond to standard treatment.

When Brad’s medullary thyroid cancer returned after a surgical procedure, he enrolled in a clinical trial. Now, his cancer is nearly undetectable.

Researchers at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, are helping shape the future of cancer care at the 2026 ASCO Annual Meeting in Chicago.

Inside the IMA203 phase III trial enrolling patients at Providence Cancer Institute.

How novelty bandages have become a beloved tradition at Providence Cancer Institute Newberg Clinic.

New ASCO guidelines are designed to make the full body of evidence accessible to clinicians across specialties, including those who may not work routinely with a head and neck surgeon.

A new medication called M3T01, developed at Providence Cancer Institute, takes a different approach to immunotherapy.

A new study focused on stories will change health outcomes for Black women.

The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.